<DOC>
	<DOCNO>NCT00003982</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness MEN-10755 treating patient solid tumor .</brief_summary>
	<brief_title>MEN-10755 Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose MEN-10755 patient solid tumor . II . Determine qualitative quantitative toxic effect drug study predictability , duration , intensity , onset , reversibility dose relationship toxic effect patient population . III . Propose safe dose phase II study . IV . Study pharmacokinetics drug different dose level patient population . V. Document possible antitumor activity drug patient population . OUTLINE : This dose escalation study . Patients receive MEN-10755 IV 15 minute day 1 , 8 , 15 . Treatment continue every 4 week , upon recovery toxicity , whichever come later . Treatment continue least 2 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos MEN-10755 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow least 3 week . PROJECTED ACCRUAL : A total 30 patient accrue study 12 month .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor amenable standard therapy Measurable evaluable disease No brain involvement leptomeningeal disease PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Liver function test great 2 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine great 1.4 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : LVEF least 50 % ( MUGA ) Other : Not pregnant nursing Fertile patient must use effective contraception No active infection No nonmalignant disease precludes study No history alcoholism , drug addiction , psychotic disorder PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , high dose carboplatin ) No concurrent antitumor drug Endocrine therapy : No concurrent corticosteroid Radiotherapy : At least 4 week since prior radiotherapy ( 6 week extensive radiotherapy ) No concurrent radiotherapy Surgery : Not specify Other : No prior anthracyclines anthracenediones No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
</DOC>